Want to see TSE:SONA full AI Analyst Report?
SONA Stock Chart & Stats
C$0.40
>-C$0.01(-2.00%)
At close: 4:00 PM EST
C$0.40
>-C$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeC$0.26 - C$0.91
Previous CloseN/A
Volume36.80K
Average Volume (3M)124.26K
Market Cap
C$32.03M
Enterprise ValueC$32.88M
Total Cash (Recent Filing)C$52.76K
Total Debt (Recent Filing)C$328.87K
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding114,375,250
10 Day Avg. Volume87,178
30 Day Avg. Volume124,263
Financial Highlights & Ratios
PEG Ratio-2.89
Price to Book (P/B)-1.80K
Price to Sales (P/S)0.00
P/FCF Ratio-35.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Gold Nanorod IP And Diagnostics FocusSona’s proprietary gold nanorod technology and explicit focus on diagnostics and life-science workflows create a durable product-led moat. If commercialized, specialty labeling materials can generate recurring B2B demand, licensing opportunities, and sticky customer relationships in research and diagnostic supply chains.
Modest Absolute Debt LevelNominal debt of ~329K TTM keeps fixed financing obligations low, preserving operational optionality relative to higher-debt peers. For an early-stage developer with negative earnings, modest debt reduces near-term bankruptcy risk and eases interest burden while management pursues commercialization or raises equity.
Reduced Losses And Cash Burn Versus Prior PeakA trend of lower losses and reduced cash burn versus the 2021 peak indicates management has narrowed the structural deficit. This improvement extends runway, suggests some cost discipline or efficiency gains, and makes achieving breakeven or sustaining development milestones more feasible without immediate dilutive financings.
Bears Say
No Reported RevenueThe absence of reported revenue means the company has not yet demonstrated commercial product-market fit. Without sales, the business cannot scale margins, prove demand, or self-fund operations, increasing reliance on external capital and raising execution risk for transitioning from R&D to commercial supplier.
Persistent Negative Operating And Free Cash FlowContinuous negative operating and free cash flow (~-1.26M TTM) creates an enduring funding gap that must be filled by capital markets. Ongoing cash burn constrains R&D, scale-up, and commercialization, increases dilution risk, and can delay product launches or regulatory steps essential for long-term revenue generation.
Shift To Negative Shareholders' EquityNegative shareholders' equity reflects cumulative losses and weak balance-sheet resilience. It reduces borrowing capacity, complicates lender and supplier relationships, and can force more dilutive financing or adverse terms. Structurally, negative equity raises the bar for profitable growth before restoring financial flexibility.
Sona Nanotech Inc News
SONA FAQ
What was Sona Nanotech Inc’s price range in the past 12 months?
Sona Nanotech Inc lowest stock price was C$0.26 and its highest was C$0.91 in the past 12 months.
What is Sona Nanotech Inc’s market cap?
Sona Nanotech Inc’s market cap is C$32.03M.
When is Sona Nanotech Inc’s upcoming earnings report date?
Sona Nanotech Inc’s upcoming earnings report date is Sep 24, 2026 which is in 77 days.
How were Sona Nanotech Inc’s earnings last quarter?
Sona Nanotech Inc released its earnings results on Jun 29, 2026. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.01.
Is Sona Nanotech Inc overvalued?
According to Wall Street analysts Sona Nanotech Inc’s price is currently Overvalued.
Does Sona Nanotech Inc pay dividends?
Sona Nanotech Inc does not currently pay dividends.
What is Sona Nanotech Inc’s EPS estimate?
Sona Nanotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sona Nanotech Inc have?
Sona Nanotech Inc has 114,375,250 shares outstanding.
What happened to Sona Nanotech Inc’s price movement after its last earnings report?
Sona Nanotech Inc reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sona Nanotech Inc?
Currently, no hedge funds are holding shares in TSE:SONA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sona Nanotech Inc
Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic test designed to detect the SARS-CoV-2 spike protein antigen in saliva from individuals suspected of having the virus. The company also offers Gemini and Omni gold nanorods, with the latter specifically engineered for medical uses, in addition to providing contract services. These versatile products are utilized in a wide array of applications, such as targeted drug delivery, environmental and food safety monitoring, cellular visualization, cancer therapy, liposuction treatments, and diagnostic tools for medical, consumer, military, and veterinary sectors.
Technical Analysis
BioMark Diagnostics
―
Eastwood Bio-Medical Canada
―
StageZero Life Sciences Ltd
―
Medmira
―
ZYUS Life Sciences
―
Options Prices
Currently, No data available
---